A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe
- 1 June 2001
- journal article
- research article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 23 (6), 871-885
- https://doi.org/10.1016/s0149-2918(01)80075-8
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Novel approaches to lipid lowering: what is on the horizon?The American Journal of Cardiology, 2001
- Novel lipid-regulating drugsExpert Opinion on Investigational Drugs, 2000
- Low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of intestinal cholesterol absorption in 243 hypercholesteremic subjects: Results of a dose-response studyAtherosclerosis, 2000
- Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663British Journal of Pharmacology, 2000
- EzetimibeDrugs of the Future, 2000
- Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)- hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol AbsorptionJournal of Medicinal Chemistry, 1998
- Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461Atherosclerosis, 1995
- Analysis of Zidovudine Distribution to Specific Regions in Rabbit Brain Using MicrodialysisPharmaceutical Research, 1992
- Estimation of area under the curve for drugs subject to enterohepatic cyclingJournal of Pharmacokinetics and Biopharmaceutics, 1985
- Pharmacokinetics and Bioavailability of Cimetidine in HumansJournal of Pharmaceutical Sciences, 1980